Triasima Portfolio Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Triasima Portfolio Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,350	Closed	-$458K	–	176
2022 Q1	$458K	Sell	4,350 -3,135	-42%	-$306K	0.02%	127
2021 Q4	$807K	Sell	7,485 -1,550	-17%	-$169K	0.04%	115
2021 Q3	$990K	Sell	9,035 -945	-9%	-$98.1K	0.05%	109
2021 Q2	$935K	Sell	9,980 -1,650	-14%	-$152K	0.05%	120
2021 Q1	$1.07M	Hold	11,630	–	–	0.05%	124
2020 Q4	$851K	Buy	+11,630	New	+$864K	0.05%	119

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Triasima Portfolio Management's HZNP Position: Q2 2022 in Review

Triasima Portfolio Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 4,350 shares — an estimated $458K sold.

Triasima Portfolio Management first reported a position in HZNP in Q4 2020 and held it in 6 quarters. The position peaked at $1.07M in Q1 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Triasima Portfolio Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Triasima Portfolio Management sold 4,350 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $458K.
Triasima Portfolio Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 6 quarters.
Triasima Portfolio Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.07M in Q1 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Triasima Portfolio Management's 13F filing for Q2 2022, filed 20 Jul 2022.